LEPR
Leptin receptor
As of the edition of 20 October 2026, LEPR (leptin receptor, UniProt P48357) has 2 drugs tested at it and 5 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P48357
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 9
- Disease areas
- Nutrition and metabolism; Skin and connective tissue; Hormones; Inherited and neonatal; Digestive system; Immune system; Mental health
- Registered trials of its drugs
- 42
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Metreleptin | Marketed | Phase 4 | Ended 2026 |
| Mibavademab | Active | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 5 |
| Total on the list | 5 |